We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Nxstage Medical, Inc. | NASDAQ:NXTM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 30.00 | 29.99 | 30.00 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
By Colin Kellaher
B. Braun Medical Inc. on Thursday said it agreed to buy NxStage Medical Inc.'s (NXTM) bloodlines business in a deal that could help pave the way for Fresenius Medical Care AG's (FME.XE, FMS) $2 billion takeover of NxStage.
B. Braun, part of closely held B. Braun Melsungen AG of Germany, said the deal adds the Streamline bloodline to its dialysis product portfolio.
The Bensalem, Pa., maker of medical products said it expects to complete the acquisition this year, contingent upon the closing of the Fresenius/NxStage deal.
In a filing with the Securities and Exchange Commission, NxStage said it agreed to the divestiture in an effort to gain FTC clearance of the Fresenius deal, which it still expects to close in 2018.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 19, 2018 10:50 ET (14:50 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Nxstage Medical Chart |
1 Month Nxstage Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
